前列腺特异性膜抗原是前列腺癌新辅助强效雄激素剥夺治疗后残留病灶的生物标志物
研究纳入35例接受强效雄激素剥夺治疗联合恩扎卢胺6个月后行根治性前列腺切除术的患者,评估抗前列腺特异性膜抗原(PSMA)抗体检测残留肿瘤的能力。31例检出残留癌,PSMA在所有病例中阳性反应,对肿瘤敏感性96%,约82%良性区域无反应;对照队列37例未治疗病例中PSMA在72%良性区域阳性,特异性28%。作者提出抗PSMA免疫染色可作为强效雄激素剥夺治疗背景下识别残留癌的标准化标志物。
要点
- 35例强效雄激素剥夺治疗联合恩扎卢胺后手术患者中31例检出残留癌,PSMA在所有病例肿瘤阳性。
- PSMA染色对肿瘤敏感性96%,约82%良性区域无反应;对照37例未治疗病例特异性28%。
- PSMA可识别包括神经内分泌分化在内的高度去分化前列腺癌。
核心结论
- 作者提出抗PSMA免疫染色可作为强效雄激素剥夺治疗背景下识别残留癌的标准化标志物。
研究设计与样本
- 研究评估抗PSMA抗体在35例接受强效雄激素剥夺治疗联合恩扎卢胺6个月后行根治性前列腺切除术的患者中检测残留肿瘤的能力。
- 对照队列为37例未治疗病例。
主要发现
- 35例中31例检出残留癌,PSMA在所有病例中与肿瘤阳性反应。
- PSMA染色对肿瘤敏感性96%,约82%良性区域无反应。
- 对照队列37例未治疗病例中PSMA与72%良性区域阳性反应,对肿瘤特异性28%。
- PSMA可识别高度去分化前列腺癌,包括有神经内分泌分化证据的肿瘤。
关键数值与推荐
- PSMA染色对肿瘤敏感性96%。
- 约82%良性区域无PSMA反应。
- 对照队列37例未治疗病例中PSMA在72%良性区域阳性,特异性28%。
临床怎么用
- 作者提出抗PSMA免疫染色可作为强效雄激素剥夺治疗背景下识别残留癌的标准化标志物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Neoadjuvant intense androgen deprivation therapy (iADT) can exert a wide range of histological responses, which in turn are reflected in the final prostatectomy specimen. Accurate identification and measurement of residual tumor volumes are critical for tracking and stratifying patient outcomes. MATERIALS AND METHODS: The goal of this current study was to evaluate the ability of antibodies against prostate-specific membrane antigen (PSMA) to specifically detect residual tumor in a cohort of 35 patients treated with iADT plus enzalutamide for 6 months prior to radical prostatectomy. RESULTS: Residual carcinoma was detected in 31 patients, and PSMA reacted positively with tumor in all cases. PSMA staining was 96% sensitive for tumor, with approximately 82% of benign regions showing no reactivity. By contrast, PSMA positively reacted with 72% of benign regions in a control cohort of 37 untreated cases, resulting in 28% specificity for tumor. PSMA further identified highly dedifferentiated prostate carcinomas including tumors with evidence of neuroendocrine differentiation. CONCLUSIONS: We propose that anti-PSMA immunostaining be a standardized marker for identifying residual cancer in the setting of iADT.
引用
- Bright JR, Lis RT, Ku AT, et al. Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer. J Urol. 2022. PMID: 35227084. doi:10.1097/JU.0000000000002492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。